Inhibikase Therapeutics, Inc.
IKT
$1.84
$0.084.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -125.79% | -90.35% | -44.62% | -2.27% | 3.40% |
| Total Depreciation and Amortization | 89.77% | -81.84% | -85.12% | -84.98% | -84.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,377.67% | 3,434.39% | 1,431.05% | -22.35% | -18.33% |
| Change in Net Operating Assets | -7.27% | -68.59% | -12.65% | 586.66% | 227.62% |
| Cash from Operations | -20.86% | -21.31% | -5.88% | 5.24% | 15.97% |
| Capital Expenditure | -- | 5.63% | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -137.56% | -188.92% | -417.06% | -101.91% | 174.47% |
| Cash from Investing | -137.65% | -189.10% | -417.45% | -101.91% | 173.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,665.89% | 25,786.51% | 1,106.09% | -55.78% | -57.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 118.09% | 100.00% | -- | -- |
| Cash from Financing | 2,776.18% | 53,325.28% | 1,131.15% | -57.21% | -59.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6,219.31% | 4,534.14% | 2,294.17% | -253.62% | 103.90% |